Back to Search
Start Over
A multi‐centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T‐prolymphocytic leukaemia or mantle cell lymphoma.
- Source :
-
British Journal of Haematology . Aug2018, Vol. 182 Issue 3, p429-433. 5p. 1 Diagram, 3 Charts. - Publication Year :
- 2018
-
Abstract
- The article reports that genetic alterations in the ataxia telangiectasia‐mutated (ATM)‐TP53 DNA damage response (DDR) pathway represent an important mechanism of chemoresistance to conventional chemotherapeutic agents and also drive genomic instability. It mentions that ATM protein plays a critical role in the DNA damage response to double strand breaks. It presents use of olaparib in patients with relapsed chronic lymphocytic leukaemia, T‐prolymphocytic leukaemia or mantle cell lymphoma.
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 182
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 130817927
- Full Text :
- https://doi.org/10.1111/bjh.14793